吉利德的中年困境:抱住CAR-T的浮木

深蓝观
28 Feb

吴妮 | 撰文又一 | 编辑回忆年轻时候的吉利德,靠着“莽撞”又大胆的收购,成为改写人类抗病毒史的颠覆者。当时的吉利德不会想到,后来追赶肿瘤免疫的路程会如此漫长。2017年收购CAR-T巨头公司Kite是吉利德正式进入肿瘤治疗领域的标志。7年过去,吉利德在ADC、单抗、双抗、CAR - T等技术路线均有涉足,但2024年肿瘤板块营收32.89亿美元,占总营收仅为11%,与抗病毒板块,特别是占总营收...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10